New Remibrutinib Data — Daily Disease Activity, Severity Band Shifts, and UCT Trajectory Through Week 52

Evaluating treatment response in chronic spontaneous urticaria has historically relied on the Urticaria Activity Score over 7 days (UAS7), a weekly composite of hive count and itch severity. Pooled data from the REMIX-1 and REMIX-2 phase 3 studies introduce a complementary daily UAS — derived from averaged morning and evening hive count and itch severity reports — that allows a more granular view of symptom trajectory from the first day of treatment. By day 7, mean daily UAS in the remibrutinib arm had fallen to 2.25, within the well-controlled threshold of less than 2.5, compared with 3.49 in the placebo group — a level consistent with moderate CSU symptoms. The categorical distribution shift is equally instructive: 37% of remibrutinib-treated patients had moved into the lowest UAS severity band by day 7, representing no or minimal symptoms, versus 9.7% on placebo. This means more than 1 in 3 patients on remibrutinib had achieved near-complete symptom resolution within the first week of treatment.

The REMIX data also capture the longer arc of disease control through the Urticaria Control Test (UCT), a validated patient-reported instrument with a well-controlled threshold of 12. At week 2, mean UCT in the remibrutinib arm was 10.5, compared with 7.3 in the placebo group — meaningfully improved but not yet at threshold. By week 12, mean UCT had risen to 11.4 in the remibrutinib group, approaching the well-controlled threshold closely. These improvements were sustained through week 52, and patients who crossed over from placebo to remibrutinib at week 24 achieved comparable UCT outcomes — reinforcing the consistency of the therapeutic effect regardless of when treatment was initiated. Together, the day-7 daily UAS data and the week-2 through week-52 UCT trajectory describe a therapy whose benefits are rapid in onset and durable over time.

In this segment of the video discussion on CSU management updates, Steve Dorman, MD, situates both data sets within the framework of patient communication. The day-7 daily UAS findings provide a concrete and evidence-supported basis for setting early expectations at the time of prescribing, while the UCT progression from week 2 through week 52 offers a practical scaffold for follow-up visits — a patient who has moved from a baseline UCT of 5 to 10.5 at week 2 has experienced a substantial transformation in disease burden even before crossing the formal well-controlled threshold, and framing that progress explicitly is an important part of sustaining engagement with therapy. Eric Karlin, MD, adds that capturing both UAS7 and UCT in practice gives the initiation and follow-up conversation a dual anchor — one instrument quantifying what the clinician observes and the other giving the patient's own experience a structured voice.